Loading clinical trials...

ACTIVE_NOT_RECRUITING

Ultra-low-dose Chest CT for HHT

Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia

NCT04874558•Mayo Clinic

View on ClinicalTrials.gov

Summary

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Eligibility

Age

1 - 17 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Ages 1 to 17 years
•Diagnosed with positive HHT causing mutations or based on Curacao criteria

Exclusion Criteria

•Acute respiratory distress
•Unstable cardiovascular status
•Pneumothorax, hemoptysis
•Pulmonary edema
•Pulmonary emboli
•Fractured ribs or other chest trauma
•Recent bronchoscopy
•Lung transplantation

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

April 21, 2021

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

July 3, 2025

Enrollment

ESTIMATED participants

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

Ultra-low dose chest CT

DIAGNOSTIC_TEST

Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

NCT07445347

Hereditary Hemorrhagic Telangiectasia (HHT)Pulmonary Hypertension+1 more

View study

COMPLETEDPHASE2

Doxycycline for Hereditary Hemorrhagic Telangiectasia

NCT03397004

Hereditary Hemorrhagic Telangiectasia (HHT)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ultra-low-dose Chest CT for HHT

Inclusion Criteria

Exclusion Criteria

Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network

Doxycycline for Hereditary Hemorrhagic Telangiectasia

Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients